JMJohn D. McCorvy

John D. McCorvy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John D. McCorvy has a total of 328 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy- N -methyl- N -isopropyltryptamine and Related Analogs

    by Grant C. Glatfelter, Serena S. Schalk, Donna Walther, Alexander D. Maitland, Nicholas R. Gonzalez, John S. Partilla, Nicholas A. Anas, Andrew R. Chadeayne, Marilyn Naeem, David R. Manke, et al.

    Tryptamine psychedelics induce psychoactive effects via agonist actions at serotonin 2A receptors (5-HT2A), but the compounds are generally nonselective. 4-Methoxy-N-methyl-N-isopropyltryptamine (4-MeO-MiPT) is a 5-HT2A agonist which also blocks the 5-HT transporter (SERT) and has blunted visual and other psychedelic effects in humans. Here, we compared the pharmacology of 4-MeO-MiPT, its 4-hydroxy derivative (4-HO-MiPT), and related analogs with N-alkyl or 4-alkoxy variations. We hypothesized that compounds with more potent SERT uptake inhibition would display reduced 5-HT2A-mediated psychedelic-like effects in the mouse head twitch response (HTR) model. In vitro target profiling revealed potent and efficacious 5-HT receptor activities for most of the compounds, including 5-HT2A receptor agonism (EC50 = 10–118 nM, Emax = 72–97% 5-HT). Importantly, 4-MeO-MiPT and its N,N-diisopropyl (4-MeO-DiPT) and N-methyl-N-cyclopropyl (4-MeO-McPT) analogs displayed more potent uptake inhibition at SERT (IC50 = 17–107 nM) than their 4-OH counterparts (IC50 = 280–423 nM). Studies administering the drugs subcutaneously to C57BL/6J mice revealed that 4-HO- and 4-MeO-MiPT (0.03–30 mg/kg) had similar potencies for inducing HTRs (ED50 = 0.75 vs 0.97 mg/kg), but 4-MeO-MiPT had reduced efficacy (Emax = 77 vs 34 HTRs/30 min). A similar trend for decreased HTRs was observed for 4-MeO-DiPT and 4-MeO-McPT. Pretreatment with the SERT inhibitor fluoxetine (10 mg/kg) prior to 4-HO-MiPT, 4-HO-DiPT, or 4-HO-McPT reduced the maximal number of HTRs to levels observed for their respective 4-MeO analogs. Overall, our data indicate that 4-MeO-MiPT interacts with 5-HT2A and other 5-HT receptors, but the drug also inhibits SERT to reduce the efficacy of psychedelic-like effects in mice. Therefore, 4-MeO-MiPT and other dual 5-HT2A/SERT ligands may be therapeutically relevant compounds with reduced potential for traditional acute psychedelic effects.


  • Open Access

    Serotonergic Polypharmacology of 2-Halogenated Tryptamines

    by Jeanine Yacoub, Elena Bray, Jude Bayyat, Grant C Glatfelter, Alex Leake, Emilia M Buitrago, Alexander D Maitland, John Partilla, Natalie G Cavalco, Serena S Schalk, et al.

    Serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) and 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin) show therapeutic promise for psychiatric and neurodegenerative disorders but may be limited by liabilities from serotonin (5-HT)-2A mediated psychoactive effects and potential cardiotoxicity via 5-HT2B activation. To address these limitations, we designed and synthesized 2-halogenated derivatives of DMT and psilacetin to reduce 5-HT2A/5-HT2B activity while retaining engagement of therapeutically relevant targets, particularly 5-HT6, 5-HT2C, and 5-HT1B. This study demonstrated that 2-position halogenation decreased affinities, potencies, and efficacies at 5-HT2A and 5-HT1A receptors while preserving potent 5-HT6 agonism, especially for 2-Br-psilocin. The analogues exhibited reduced affinities at 5-HT2B and hERG ion channels, suggesting safer cardiac valve and cardiotoxic profiles. In C57BL/6J mice, 2-Br-psilacetin did not induce the head-twitch response and attenuated 2,5 dimethoxy-4-iodoamphetamine (DOI)-induced head-twitch behavior, suggesting a reduced potential for inducing psychedelic effects. Behavioral assays further revealed improvements in stress-induced affective measures and hippocampus-independent cued learning at intermediate doses. These findings identify 2-halogenated tryptamines as polypharmacological serotonergic ligands with reduced psychoactivity and cardiac valve and toxic liabilities, supporting their potential as next-generation psychedelic-inspired therapeutics.


  • Open Access

    Correction to “Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights”

    by Nina Kastner, Núria Nadal-Gratacós, Selina Hemmer, Leticia Alves da Silva, John L. McKee, Tamara Hell, Giulia Cicalese, Marion Holy, Fatemeh Kooti, Kathrin Jäntsch, et al.

  • Top Cited Papers
    Open Access

    Biased Signaling in Psychedelic Action

    by Daniel Wacker, John D. McCorvy

    Psychedelics show tremendous promise for treating psychiatric disorders and other illnesses, including pain and migraine. Despite decades of research, there is uncertainty which signaling mechanisms are necessary for rapid-acting and durable therapeutic effects of psychedelics. Although activation of the serotonin 5-HT 2A receptor is critical for their psychopharmacological effects, the precise signaling pathways and receptor conformations responsible are still under investigation. This review summarizes progress in studying 5-HT 2A signaling mechanisms and recent developments in the discovery of biased agonist tool compounds to disentangle therapeutic from adverse effects. Moreover, we review insights from structural studies regarding the design of psychedelic-derived compounds with tailored pharmacology and briefly discuss other 5-HT receptors that may be important for shaping therapeutic effects. Finally, by drawing parallels between 5-HT 2A biased signaling and the opioid field, we conclude with lessons learned and discuss the need for more rigor and reproducibility to facilitate the development of novel psychedelic-based pharmacotherapies.


  • Transforming Amino Acids into Serotonin 5-HT 2A Receptor Ligands Using Photochemistry

    by Joseph O. S. Beckett, Ryan Buzdygon, Steven Nguyen, Allison A. Clark, Serena S. Schalk, Lena E. H. Svanholm, Trey J. Brasher, Marc Bazin, Bruna Cuccurazzu, Adam L. Halberstadt, et al.

    A light-induced cyclization via a radical spin-center shift process that results in the direct functionalization of the indole ring at the C4-position is developed into a practical method for the synthesis of medicinally active, ring-constrained tryptamine analogs. Amino acids were coupled to tryptamine and irradiated with UV light to produce a library of lactams bridging the C3- and C4-positions of the indole nucleus. An extension to this method is introduced that employs α-acetoxy- and α-lactone-substituted tryptamides. Using optimized conditions and these easily accessed precursors, C3- to C4-bridged indoles can now be produced in good to excellent yields, free of the C2-regioisomers that are often seen using α-halo tryptamide substrates. Due to the structural similarities of the reduced lactams (azocinoindoles) with known psychoactive tryptamines, their functional activation at the serotonin 5-HT2A receptor was investigated both in silico and in vitro. These azocinoindoles show both full and partial agonist 5-HT2A Gq activation efficacies and suppress the head-twitch response in vivo, suggesting they belong to an emerging class of nonhallucinogenic 5-HT2A agonists. The azocinoindole core and the synthetic advances described here that enable its structural diversification provide a valuable platform for serotonin receptor drug discovery.


  • Open Access

    Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights

    by Nina Kastner, Núria Nadal-Gratacós, Selina Hemmer, Leticia Alves da Silva, John L. McKee, Tamara Hell, Giulia Cicalese, Marion Holy, Fatemeh Kooti, Kathrin Jäntsch, et al.

    3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, shows promise in treating depression and post-traumatic stress disorder (PTSD), resulting in breakthrough status. However, concerns regarding MDMA's abuse potential and cytotoxicity have sparked interest in developing safer analogues with similar therapeutic benefits. This study investigated the pharmacological properties of MDMA analogues in which the 1,3-benzodioxole group is replaced by a 1,3-benzoxathiole, termed SDA and SDMA, compared to MDA and MDMA through in silico, in vitro, and in vivo assays. In vitro experiments using human embryonic kidney (HEK293) cells examined the interactions with monoamine transporters. SDA and SDMA showed similar profiles to MDMA at the serotonin transporter (SERT), while both inhibited dopamine (DAT) and norepinephrine (NET) transporters more potently, in line with in silico molecular docking fitness scores of binding. SDA and SDMA also showed increased potency in evoking efflux through SERT and DAT acting as partial releasers. SDA and SDMA exhibited a similar interaction profile with 5-HT2 receptors compared with their respective analogues. Metabolism studies revealed faster clearance rates for SDA and SDMA, in contrast to MDA and MDMA, which exhibited only weak degradation. In contrast to MDMA's rewarding effects, SDMA did not induce significant effects in mice, while SDA only produced a significant preference for the drug-paired compartment at the lowest dose tested. Moreover, while SDMA shares similar locomotor and hyperthermic profiles as MDMA in mice, SDA induced increased hyperlocomotion and more sustained hyperthermia. In conclusion, these findings suggest that SDMA, with enhanced metabolic profiles and reduced abuse potential, is a promising candidate for further studies.

  • Discovery of Highly Selective 5-HT2A Agonists Using Structure-Guided Design

    by Tyler G. Fenske, John L. McKee, Natalie G. Cavalco, Serena S. Schalk, Emma M. Bonniwell, Josie C. Lammers, Naomi Shacham, Bruna Cuccurazzu, Adam L. Halberstadt, John D. McCorvy

    With a resurgence in interest in psychedelics as rapid-acting and durable neuroplastic therapies, there is a critical need to develop more selective 5-HT2A agonists to investigate the basic neurobiological mechanisms of psychedelics. Here, we show that selectivity for 5-HT2A over the closely related 5-HT2C receptor can be leveraged using structure-based design to target residue L1232.53 in transmembrane 2 (TM2) of the extended binding pocket by increasing steric aliphatic bulk on the α-methylene group of the N-benzyl chemical scaffold. Furthermore, we comprehensively confirm selectivity at 5-HT2C RNA editing isoforms, TM2 reciprocal 5-HT2A and 5-HT2C mutants, and mouse 5-HT2A and 5-HT2C orthologs, to form a complete profile for highly selective 5-HT2A agonists to date. Using a combination of structure–activity relationships, molecular docking, and mouse head-twitch response assays, we show that 5-HT2A-selective agonists can be rationally designed to improve 5-HT2A target engagement, further advancing the study into the neurobiological mechanisms of psychedelic effects.


  • Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism

    by Emma M. Bonniwell, Rana Alabdali, Joseph J. Hennessey, John L. McKee, Natalie G. Cavalco, Josie C. Lammers, Ethan J. Moore, Luca Franchini, Cesare Orlandi, John D. McCorvy

    The serotonin 2C receptor (5-HT2C) is a G protein-coupled receptor implicated in multiple physiological and psychological processes and has been investigated as a therapeutic target for neuropsychiatric conditions such as obesity, drug abuse, and depression. With renewed interest in serotonergic psychedelics for treating depression, 5-HT2C may contribute to psychedelic-induced therapeutic effects. Despite earlier evidence of 5-HT2C G protein coupling promiscuity, the full signaling landscape remains incompletely characterized, which may help explain the limited efficacy and potential cancer risks associated with lorcaserin. Here, we provide a comprehensive analysis of 5-HT2C signaling, confirming and building upon previous findings that the receptor engages Gi/o/z and G12/13 proteins in addition to its primary Gq/11 pathway, and that it preferentially recruits β-arrestin2 over β-arrestin1. We also show that increased RNA editing of the receptor attenuates signaling across all G protein pathways, particularly for G12/13, while preserving β-arrestin recruitment. Profiling of both 5-HT2C-selective and psychedelic ligands reveals diverse signaling profiles, with serotonergic psychedelics such as LSD and psilocin exhibiting a striking Gq/11 bias due to minimal secondary G protein activation. Altogether, this work provides a foundation for incorporating a broader view of 5-HT2C signaling modalities into future investigations of 5-HT2C drug development efforts.


  • Open Access

    A Novel Class of Complement 3a Receptor Agonists and Antagonists Derived from the TLQP-21 Peptide

    by Pedro Rodriguez, Jean Pierre Pallais, Rongjun He, Maria Razzoli, John L. McKee, Hailey A. Bock, John D. McCorvy, Yuk Y. Sham, Richard DiMarchi, Alessandro Bartolomucci

    The complement 3a receptor (C3aR) is a G-protein-coupled receptor (GPCR) involved in inflammatory, metabolic, and neurological diseases. Two endogenous ligands (C3a and TLQP-21) and small molecules (SB290157 and JR14a) differentially signal at C3aR, but these properties are not fully understood and need to be optimized with medicinal chemistry. Here, we generated rationally designed peptidergic analogues of TLQP-21 in an effort to extend the range of compounds with therapeutic potential beyond C3a-derived peptidergic agonists or small-molecule antagonists. We identified key arginines in the central portion of the peptide and the C-terminus, where mutation confers enhanced plasma stability. Mutations at the C-terminal motif alanine-arginine (-AlaArg), with unnatural amino acids and stereoisomers conferred signaling selectivity, enhanced peptide potency (e.g., DArg10_DAla20), or resulted in a functional antagonist (DArg10_Aib20). Overall, we increased our understanding of the C3aR mechanism of action, expanding and differentiating the range of therapeutic potentials for this GPCR.


  • Open Access

    The ABCs of psychedelics: a preclinical roadmap for drug discovery

    by Alex C. Kwan, John R. Mantsch, John D. McCorvy